ReviewMalaria journal2012
The global pipeline of new medicines for the control and elimination of malaria.
Review in Malaria journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Geographical variation in Plasmodium vivax relapse.Malaria journal · 2014Pooled it
- New thinking for the next generation of antimalarials.EMBO molecular medicine · 2026Review
- Modulation of Various Pharmacological Pathways by Asparagus Saponins: Special Emphasis on Shatavarin-IV.Chemistry & biodiversity · 2026Review
- Immunoinformatics-Based Multi-Epitope Vaccine Design AgainstHealth science reports · 2025Article
- The human malaria-Antimicrobial agents and chemotherapy · 2024Review
- Artemisinin-naphthoquine plus lower-dose primaquine to treat and prevent recurrence of Plasmodium vivax malaria: an open-label randomized and non-inferiority trial.Parasites & vectors · 2024Article
- Current and emerging target identification methods for novel antimalarials.International journal for parasitology. Drugs and drug resistance · 2022Review
- Optimized Pyridazinone Nutrient Channel Inhibitors Are Potent and Specific Antimalarial Leads.Molecular pharmacology · 2022Article
- Potential antibacterial and antifungal activities of novel sulfamidophosphonate derivatives bearing the quinoline or quinolone moiety.Archiv der Pharmazie · 2021Article
- A novel class of fast-acting antimalarial agents: Substituted 15-membered azalides.British journal of pharmacology · 2021Article
- Enhancing the antimalarial activity of artesunate.Parasitology research · 2020Review
- Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistantActa pharmaceutica Sinica. B · 2020Article
- Functionalized Naphthalimide-4-aminoquinoline Conjugates as Promising Antiplasmodials, with Mechanistic Insights.ACS medicinal chemistry letters · 2020Article
- Alkaloids from Plants with Antimalarial Activity: A Review of Recent Studies.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- The Development of Novel Compounds Against Malaria: Quinolines, Triazolpyridines, Pyrazolopyridines and Pyrazolopyrimidines.Molecules (Basel, Switzerland) · 2019Review
- Mushrooms: an emerging resource for therapeutic terpenoids.3 Biotech · 2019Review
- The antimalarial screening landscape-looking beyond the asexual blood stage.Current opinion in chemical biology · 2019Review
- Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics.Pharmaceutical research · 2018Review
- The MEP pathway in Babesia orientalis apicoplast, a potential target for anti-babesiosis drug development.Parasites & vectors · 2018Article
- Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein.Scientific reports · 2018Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decade, there has been a transformation in the portfolio of medicines to combat malaria. New fixed-dose artemisinin combination therapy is available, with four different types having received approval from Stringent Regulatory Authorities or the World Health Organization (WHO). However, there is still scope for improvement. The Malaria Eradication Research agenda identified several gaps in the current portfolio. Simpler regimens, such as a single-dose cure are needed, compared with the current three-day treatment. In addition, new medicines that prevent transmission and also relapse are needed, but with better safety profiles than current medicines. There is also a big opportunity for new medicines to prevent reinfection and to provide chemoprotection. This study reviews the global portfolio of new medicines in development against malaria, as of the summer of 2012. Cell-based phenotypic screening, and 'fast followers' of clinically validated classes, mean that there are now many new classes of molecules starting in clinical development, especially for the blood stages of malaria. There remain significant gaps for medicines blocking transmission, preventing relapse, and long-duration molecules for chemoprotection. The nascent pipeline of new medicines is significantly stronger than five years ago. However, there are still risks ahead in clinical development and sustainable funding of clinical studies is vital if this early promise is going to be delivered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.